Eligible adult women with newly diagnosed ovarian cancer that was either high-risk early-stage disease ( International Federation of Gynecology and Obstetrics [ FIGO ] stage I-IIa , grade 3 or clear cell histology ) or more advanced disease ( FIGO stage IIb-IV ) , with an Eastern Cooperative Oncology Group performance status of 0-2 , were enrolled and randomly assigned in a 1:1 ratio to standard chemotherapy ( six 3-weekly cycles of intravenous carboplatin [ AUC 5 or 6 ] and paclitaxel 175 mg/m ( 2 ) of body surface area ) or the same chemotherapy regimen plus bevacizumab 75 mg per kg bodyweight intravenously every 3 weeks , given concurrently and continued with up to 12 further 3-weekly cycles of maintenance therapy .